Greg Simon, MD, MPH, is a psychiatrist and senior investigator well-known for his extensive research on practical approaches to improving mental health care. He seeks to develop and evaluate effective real-world strategies that support better mental health and wellness. Current areas of emphasis include identifying and assessing suicide risk, improving care for treatment-resistant depression, and reducing racial and ethnic disparities in mental health care.
Dr. Simon leads the Mental Health Research Network (MHRN), a consortium of research centers affiliated with 13 large health systems across the United States, including Kaiser Permanente Washington. This network, originally funded through a cooperative agreement with the National Institute of Mental Health, aims to improve the efficiency, relevance, and impact of mental health clinical and health services research. The MHRN is exploring a broad range of issues—including suicide prevention, improving heart health in people with serious mental illness, using electronic medical records to improve follow-up care for depression, and understanding the causes of racial and ethnic disparities in mental health care.
Dr. Simon and his MHRN colleagues have conducted several large studies across MHRN health systems, including:
Dr. Simon sits on the editorial board for the journal General Hospital Psychiatry, and co-chairs the National Academy of Medicine’s Forum on Drug Discovery, Development and Translation.. Dr. Simon has practiced adult psychiatry in Kaiser Permanente Washington's Mental Health and Wellness Service since 1990. He is also a professor in the department of Health Systems Science at the Bernard J Tyson Kaiser Permanente School of Medicine and an adjunct professor inPsychiatry and Behavioral Dciences at the University of Washington.
Depression; bipolar disorder; suicide prevention; self-management; treatment adherence
Comorbidity of mental health conditions with obesity, diabetes, heart disease, and substance use disorders.
Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry. 2007;164(7):1029-34. PubMed
Ludman EJ, Simon GE, Tutty S, Von Korff M. A randomized trial of telephone psychotherapy and pharmacotherapy for depression: continuation and durability of effects. J Consult Clin Psychol. 2007;75(2):257-66. PubMed
Linde JA, Jeffery RW, Finch EA, Simon GE, Ludman EJ, Operskalski BH, Ichikawa L, Rohde P. Relation of body mass index to depression and weighing frequency in overweight women. Prev Med. 2007;45(1):75-9. Epub 2007 Mar 31. PubMed
Simon GE, Katon WJ, Lin EH, Rutter C, Manning WG, Von Korff M, Ciechanowski P, Ludman EJ, Young BA. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry. 2007;64(1):65-72. PubMed
Simon GE. The antidepressant quandary--considering suicide risk when treating adolescent depression. N Engl J Med. 2006;355(26):2722-3. PubMed
Wang PS, Patrick A, Avorn J, Azocar F, Ludman E, McCulloch J, Simon G, Kessler R. The costs and benefits of enhanced depression care to employers. Arch Gen Psychiatry. 2006;63(12):1345-53. PubMed
Ludman E, Katon W, Russo J, Simon G, Von Korff M, Lin E, Ciechanowski P, Kinder L. Panic episodes among patients with diabetes. Gen Hosp Psychiatry. 2006;28(6):475-81. PubMed
Simon GE. How can we know whether antidepressants increase suicide risk? Am J Psychiatry. 2006;163(11):1861-3. PubMed
Simon GE, Ludman EJ, Operskalski BH. Randomized trial of a telephone care management program for outpatients starting antidepressant treatment. Psychiatr Serv. 2006;57(10):1441-5. PubMed
Simon GE, Ludman EJ. Outcome of new benzodiazepine prescriptions to older adults in primary care. Gen Hosp Psychiatry. 2006;28(5):374-8. PubMed
In a new multistate study, the Zero Suicide Model reduced suicide rates by 25%.
Safety planning and risk screening improved outcomes for adult patients.
A new grant funds modeling work to make personalized treatment possible.
KPWHRI research finds ways to increase use of a firearm safety tool.
Study finds that many patients who might benefit from clozapine don’t receive it.